A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL

Clinical trial NCT05806099 · RECRUITING

Trial details

NCT number: NCT05806099
Sponsor: Beijing Mabworks Biotech Co., Ltd.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Non-Hodgkin's Lymphoma

Start date: 2023-06-28
Primary completion: 2025-11-01
Enrollment: 132

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.